5MZ3

P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide]

Summary for 5MZ3

Entry DOI	10.2210/pdb5mz3/pdb
Descriptor	Mitogen-activated protein kinase 14, ~{N}-[3-(2-acetamidoimidazo[1,2-a]pyridin-6-yl)-4-methyl-phenyl]-3-(trifluoromethyl)benzamide (3 entities in total)
Functional Keywords	kinase, inhibitor, phosphotransferase, transferase
Biological source	Homo sapiens (Human)
Total number of polymer chains	1
Total formula weight	42897.79
Authors	Cowan-Jacob, S.W.,Scheufler, C. (deposition date: 2017-01-30, release date: 2017-11-15, Last modification date: 2018-11-07)
Primary citation	Smith, A.,Ni, Z.J.,Poon, D.,Huang, Z.,Chen, Z.,Zhang, Q.,Tandeske, L.,Merritt, H.,Shoemaker, K.,Chan, J.,Kaufman, S.,Huh, K.,Murray, J.,Appleton, B.A.,Cowan-Jacob, S.W.,Scheufler, C.,Kanazawa, T.,Jansen, J.M.,Stuart, D.,Shafer, C.M. Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors. Bioorg. Med. Chem. Lett., 27:5221-5224, 2017 Cited by PubMed: 29107542 DOI: 10.1016/j.bmcl.2017.10.047 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (2.15 Å)

Structure validation